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Summary 
A series of 111 thiosemicarbazones of  2-acetylpyridine, 2-acetylquinoline, 1-acetyl- 
isoquinoline, and related compounds were evaluated as inhibitors of  herpes simplex 
virus in vitro and in a cutaneous herpes guinea pig model. All derivatives tested were 
potent inhibitors of  virus replication with mean 50% inhibitory concentrations of  1.1 
~tg/ml for both type 1 and 2 herpes simplex virus. Inhibitory concentrations for cellular 
protein and DNA synthesis were considerably higher for many compounds resulting in 
in vitro therapeutic indices ranging from ~, 100 (highly selective) to < 1 (negatively 
selective). 
All compounds were tested for dermal toxicity following topical administration of 
saturated solutions in 1,3-butanediol to the shaved, depilated skin of guinea pigs. 
Approximately 50% of the compounds produced slight to no dermal toxicity whereas 
the remaining compounds produced moderate to severe dermal toxicity. 
28 compounds were evaluated in the cutaneous herpes guinea pig model against 
herpes simplex virus type 1. A number  of N4-monosubstituted 2-acetylpyridine thio- 
* Correspondence regarding this paper should be directed to Dr. Charles Shipman, Jr., The University 
of Michigan, School of Dentistry, Department of Oral Biology, Ann Arbor, MI 48109, U.S.A. Phone 
(313) 763-3331. 
** Present address: Warner Lambert-Parke Davis, Pharmaceutical Research Division, Ann Arbor, MI 
48105, U.S.A. 
0166-3542/86/$03.50 © 1986 Elsevier Science Publishers B.V. (Biomedical Division) 
198 
semicarbazones produced highly significant reductions in days to healing and lesion 
score without producing untoward dermal toxicity. 
Structure-activity relationships revealed that a reduction of the azomethine bond in 
the molecule (i.e., conversion of a thiosemicarbazone to a thiosemicarbazide) greatly 
diminished dermal toxicity apparently without producing a proportional decrease in 
antiviral activity. 
thiosemicarbazones; antiviral compounds; herpes simplex virus; in vitro testing; 
guinea pig model; topical therapy 
Introduction 
The antiviral activity of thiosemicarbazones was reported first in 1950 by Hamre et 
al. [15] who found that derivatives of benzaldehyde thiosemicarbazone were active 
against neurovaccinial infection in mice when given orally. This prompted further 
investigation of other thiosemicarbazones. The thiosemicarbazone of isatin was found 
to be one of the most active [3], and a clinical trial of the N-methyl derivative of 
isatin-13-thiosemicarbazone (methisazone) was carried out in India [4-6]. The studies 
indicated that the drug was effective in the prevention of smallpox in persons exposed 
to the disease. Although these studies have been widely accepted as evidence of the 
effective antiviral activity of methisazone in humans, a subsequent field trial study 
demonstrated little efficacy [16]. The drug has been used also to treat patients with 
genital lesions caused by herpes simplex virus (HSV), but it had little effect on the 
severity or duration of the lesions [17]. 
Sidwell and co-workers evaluated a series of purine analogs as antiviral agents and 
demonstrated that purine-6-carboxaldehyde thiosemicarbazone was effective in sup- 
pressing both the cytopathic effect and the titers of human cytomegalovirus [27]. This 
was the first report of a substituted thiosemicarbazone being active against a herpesvi- 
rus. In addition, the effect of heterocyclic thiosemicarbazones was examined by 
Brockman and co-workers [7]. They tested the effect of several pyridine, isoquinoline, 
purine, and isatin derivatives on herpes simplex virus (HSV) and found that only those 
compounds in which the thiosemicarbazide moiety was affixed to the heterocyclic ring 
in the alpha position relative to the ring nitrogen were active. For example, the 
2-formylpyridine derivative was active, whereas the 3-formylpyridine and 4-formylpy- 
ridine derivatives were inactive. 
Thiosemicarbazones of 2-acetylpyridine have been found by Klayman et al. [ 18,19] 
to exhibit antimalarial activity in mice infected with Plasmodium berghei. Transition 
metal complexes of several 2-acetylpyridine thiosemicarbazones also have been 
prepared and tested for antimalarial properties [23]. 
Dobek and associates have reported [10,11] that many of the 2-acetylpyridine 
thiosemicarbazones described by Klayman et al. [18,19] were very active against 
Neisseria gonorrhoeae and N. meningitidis. Using a number of culturable mycobacteria 
in vitro, Collins and co-workers [9] have reported that significant activity was 
observed with a number of derivatives of 2-acetylpyridine thiosemicarbazone. 
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We have been investigating the anti-herpesvirus activity of these thiosemicarba- 
zones and have found that selected 2-acetylpyridine thiosemicarbazones inhibited the 
replication of herpes simplex virus types 1 and 2 (HSV- 1 and HSV-2) to a greater extent 
than cellular DNA or protein synthesis [26]. The present communication extends these 
preliminary laboratory studies and presents additional data derived from a cutaneous 
herpes guinea pig model. 
Materials and Methods 
In vitro studies 
The source of cells and HSV-1 (HF strain), the routine growth and passage of 
BHK-21/4 cells and KB cells, the propagation and titration of HSV, the techniques 
used for the enumeration of cells, and the detection of mycoplasma contamination are 
described elsewhere [25]. HSV-2 (X79 strain) was kindly provided by Dr. Earle Kern 
(University of Utah). 
The 2-acetylpyridine thiosemicarbazones were evaluated by means of a series of 
biochemical tests and virological assays previously described in detail [26]. In brief, the 
testing procedure consisted of examining the effects of candidate substances on titers 
of HSV-1 and HSV-2 undergoing replication and of conducting a battery of four 
biochemical tests to determine the effects of the candidate substances on cellular 
growth and metabolism as measures of cytotoxicity. The four biochemical tests were 
(i) [3H]amino acid incorporation into acid-precipitable material, (ii) [3H]thymidine 
incorporation into acid-precipitable material, (iii) DNA synthesis as measured by 
diphenylamine assays [8], and (iv) protein synthesis as measured by Lowry assays [20]. 
Dose-response relationships were constructed by linearly regressing log drug 
concentrations against the percent inhibition values derived for viral replication, 
incorporation of [3H]thymidine or [3H]amino acids, total protein, or total DNA. The 
50% inhibitory concentrations were calculated from the regression lines by using 
methods previously described [12]. Samples containing arabinosyladenine (vidara- 
bine, ara-A, provided through the courtesy of Dr. H.E. Machamer, Parke, Davis & 
Co., Detroit, MI) at a concentration of 10 ~tg/ml were included in all assays as a 
positive control. Results from sets of assays were rejected whenever inhibition by 
ara-A deviated from its mean response by more than 1.5 standard deviations. 
In order to be able to compare and rank compounds on the basis of their selective 
inhibition of viral replication versus cellular protein and DNA biosynthesis, an index 
we have called the 'in vitro therapeutic index' was derived. We define the index as the 
average 50% inhibitory concentration for cellular protein and DNA synthesis divided 
by the 50% inhibitory concentration for viral replication. Thus for the dimethyl 
derivative of 2-acetylpyridine thiosemicarbazone (compound 27), the in vitro thera- 
peutic index for HSV-1 would be [(2.0 + 2.1 + 0.24 + 1.8)/4] / 0.08 = 19. Similarly, 
dividing the resulting numerator by 0.17 would yield a value of 9 for HSV-2. 
Animal studies 
For the 5-day test of dermal toxicity, adult female guinea pigs weighing 300-400 g 
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were shaved, depilated chemically, washed and dried. The hairless area was divided 
into six sections with a marking pen. Five areas were treated topically twice per day for 
5 days with 0.7% solutions or suspensions of candidate compounds in 1,3-butanediol 
(99+%, Aldrich Chemical Co., Milwaukee, WI). The sixth area received solvent only. 
Each compound was tested on two animals. Dermal toxicity was scored as none (0), 
very slight (+), slight (+), moderate (++) ,  or severe ( + + + ) .  
In the 14-day test for reduction of HSV-1 lesions, adult female guinea pigs weighing 
300-400 g were shaved, depilated chemically, washed and dried under anesthesia 
(Innovar). The hairless area was divided into six squares with a marking pen. In the 
center of each area 25 pl of strain S-148 HSV-1 (kindly supplied by Dr. Thomas 
Schafer, Schering Corporation, Bloomfield, N J) at a titer of 3.2 × 106 PFU/ml  was 
applied. The virus was inoculated under anesthesia with a spring-loaded vaccination 
instrument (Sterneedle Gun, Panray Division, Ormont Drug Co., Englewood, N J), 
which was released 10 times producing inoculations 0.75 mm deep on each skin area. 
The procedure is essentially according to Schafer et al. [22] and Alenius and 0berg  [1]. 
Three to four areas on each animal were treated topically twice per day for 5 days 
beginning 24 h after inoculation with 50 pl of varying concentrations of candidate 
compounds as solutions or suspensions in 1,3-butanediol. One or two areas on each 
animal received solvent alone and served as the control site(s). One area was treated 
with either trisodium phosphonoformate (a gift of Dr. John Boezi, Michigan State 
University, East Lansing, MI) [2] or 2-acetylpyridine thiosemicarbazone (compound 
1), compounds exhibiting known antiviral activity, as a positive control. When 
different substituted thiosemicarbazones were compared, one area on each animal was 
used for each substance. Seven parallel areas (seven animals) were used in most 
experiments. Any dermal toxicity due to the test compounds was noted. 
To quantitate the effect of antiviral compounds, the scoring system of Alenius and 
0berg  [ 1] was used. After inoculation of the guinea pigs with HSV as described above, 
the inoculated areas were scored daily for 14 days. The animals were depilated every 3 
or 4 days to facilitate observation. All scoring was done blind. Time to healing was 
noted also for each drug. A statistical program was developed to analyze the data using 
techniques of profile analysis, paired t-tests and analysis of variance. 
Virus titers in infected skin were measured to confirm that the drugs inhibited viral 
replication and were not simply acting as anti-inflammatory agents. Guinea pigs were 
killed and the individual areas of inoculation sites excised. Skin samples were frozen 
and thawed once, minced with scissors, and homogenized (Tissumizer, Tekmar Co., 
Cincinnati, OH) in ice-cold Hepes-buffered saline [24] (pH 7.4) containing 100 units of 
penicillin and 100 lag of streptomycin, respectively, per ml. The suspensions were 
centrifuged at 1000 × g and the centrifugate stored at -76°C for subsequent assay in 
BHK-21/4 cells according to the procedure of Shipman et al. [25]. 
Results 
In vitro studies 
Tables 1 through 8 summarize the 50% inhibitory concentrations determined for 
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111 related thiosemicarbazones. All derivatives tested (65 against HSV-1 and 15 
against HSV-2) were potent inhibitors of virus replication with mean 50% inhibitory 
concentrations of 1.1 + 0.22 (S.E.) lag/ml for HSV-I and 1.1 + 0.42 lag/ml for HSV-2. 
When paired data for the 15 compounds tested against both types of herpes simplex 
virus were compared, the resulting means for HSV-1 and HSV-2 were 1.1 -t- 0.36 lag/ml 
and 1.1 -t- 0.42 lag/ml, respectively. Some compounds (27, 30, 46, 51, 68, and 93) were 
exceptionally potent inhibitors of viral replication with 50% inhibitory concentrations 
ranging from 40 to 90 ng/ml. 
Over 60 compounds were evaluated by both an isotopic and a nonisotopic method 
to determine 50% inhibitory concentrations for protein biosynthesis. There was good 
agreement between the two procedures with mean 50% inhibitory concentrations for 
uptake of [3H]amino acids of 20.0 5:10.2 (S.E.) lag/ml and 17.8 -t- 9.3 lag/ml for the 
Lowry method. Compounds varied widely in their capacity to inhibit protein synthe- 
sis. The two unsubstituted compounds, 2-acetylpyridine thiosemicarbazone (com- 
pound 1) and the semicarbazone analog (compound 106), had little effect on protein 
synthesis. Other compounds (see, for example, 53 and 68) with bulky substitutions at 
N 4 were potent inhibitors of protein synthesis. 
Overall, the correlation between values derived for an isotopic and a nonisotopic 
method for measuring inhibition of DNA synthesis was satisfactory. Again, over 60 
compounds were evaluated with resulting mean 50% inhibitory concentrations of 11.0 
5:9.3 (S.E.) lag/ml for the uptake of [3H]thymidine and 15.1 5:9.8 lag/ml for the 
diphenylamine assay. There were, however, several cases where inhibition of the 
uptake of [3H]thymidine was considerably greater than inhibition of DNA synthesis as 
measured by the nonisotopic method (see, for example, compounds 1, 2, 21, and 95). 
We have observed a similar disparity with the drug ribavirin and have determined that 
it was due to potent inhibition of the phosphorylation of [3H]thymidine rather than 
inhibition of DNA synthesis [13]. 
In vitro therapeutic indexes were computed for 56 compounds against HSV-I and 
for 15 compounds against HSV-2. Values ranged from/> 100 (highly selective) to < 1 
(negatively selective). For comparison, the in vitro therapeutic index of arabinosylade- 
nine in this system is approximately 3 (data not shown). The inference that the 
compounds act more selectively against HSV-2 must await confirmation with a larger 
number of compounds and additional strains of HSV-I and HSV-2. In absolute 
numbers, three compounds (1, 2, and 105) produced in vitro therapeutic indexes of 
/> 100 for both HSV-1 and HSV-2. Only the adamantyl derivative of 2-acetylpyridine 
thiosemicarbazone had an in vitro therapeutic index > 100 for HSV-2 and < 100 for 
HSV-1. 
Animal studies 
Saturated solutions (normally 0.7-1%) in 1,3-butanediol of all compounds listed in 
Tables 1 through 8 were evaluated for dermal toxicity in guinea pigs. 20% of the 
compounds produced no dermal toxicity. Very slight toxicity (mild erythema in two or 
three animals out of seven) was seen in 14% of the compounds. Mild erythema was 
noted in another 14% of the test animals (one out of seven animals), while moderate 






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































moderate and severe dermal toxicity, induration accompanied the erythema, and in 
severe dermal toxicity, desquamation followed. Further application of compound was 
stopped when severe dermal toxicity was observed. 
28 compounds were evaluated in the cutaneous herpes guinea pig model. The usual 
criteria for selecting compounds for evaluation in this model were (i) an in vitro 
therapeutic index ~ 10 and (ii) a score o f+ ,  +,  or 0 in the dermal toxicity test described 
in the above paragraph. The therapeutic effects of these compounds at various 
concentrations in 1,3-butanediol were compared after topical application on animals 
infected with HSV- 1 (strain S- 148). Treatment was initiated 24 h after inoculation. Fig. 
1 illustrates the time course of the infection after application of placebo (1,3-butane- 
diol), a saturated solution of compound 5 (0.7%, w/v), 0.32% drug, 0.1% drug, and 
0.032% drug. It is clear that although a 0.032% solution of this compound did not 
significantly reduce symptoms at any time during the infection, concentrations of 
0.1%, 0.32%, and 0.7% drug reduced total lesion score by 23%, 63%, and 85%, 
respectively. For  comparison, 5% acyclovir in a polyethylene glycol base (Zovirax® 
ointment 5%, Burroughs Wellcome Co., Research Triangle Park, NC) reduced total 
lesion score by 39% in this model (data not shown). Confirming results obtained in the 
dermal toxicity test using unabraded skin, compound 5 produced only a slight and 
transient dermal toxicity in some of the animals. Using similar procedures and 
analyses, 11 of the 28 compounds were shown to produce statistically significant 
reductions in lesion scores, whereas 17 of the 28 compounds tested were without 
effect. 
Virus titers in the skin of placebo-treated and drug-treated animals were determined 
on day 4 following virus inoculation. Previous studies by others [22] and in our own 
laboratory (data not shown) have demonstrated that virus titers reach a peak on day 4 
in both untreated and treated animals. For  the determination of skin titers, four 
animals were killed 4 days after virus inoculation. Sections of the skin were aseptically 
3 
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0 2 4 6 8 40 
Days After Virus Inoculotion 
Fig. 1. Effect of 2-acetylpyridine 4-allyl-3-thiosemicarbazone (compound 5) on HSV-I lesions in the 
cutaneous herpes guinea pig model. Treatment was started 24 h after inoculation and consisted of 2 daily 












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































removed and processed as described in Materials and Methods (see above). Compar- 
ing vehicle alone with 1% compound 1 (a compound shown in separate experiments 
to be approximately as efficacious as compound 5 in the cutaneous herpes guinea pig 
model), the drug produced approximately a 70% reduction in virus titer (from a mean 
of 1.0 × 104 PFU/ml  to 3.1 × 103 PFU/ml). This difference, albeit not dramatic, was 
statistically highly significant (P = 0.0001). 
Discussion 
The experiments presented here, which describe the potent inhibition of the replica- 
tion of herpes simplex virus types 1 and 2 in both in vitro and in vivo situations by 
derivatives and compounds closely related to 2-acetylpyridine thiosemicarbazone, 
have been directed toward elucidating structure-activity relationships. For the pur- 
poses of this discussion, compounds will be considered as being N4-monosubstituted 
2-acetylpyridine thiosemicarbazones (class I), N4,N4-disubstituted (noncyclic) 2-ace- 
tylpyridine thiosemicarbazones (class II), N4,N4-disubstituted (azacyclic) 2-acetylpyri- 
dine thiosemicarbazones (class III), derivatives of other 2-acetylpyridine thiosemi- 
carbazones (class IV), 2-acetyl-6-methylpyridine thiosemicarbazones (class V), 
2-acetylquinoline thiosemicarbazones and thiosemicarbazides (class VI), 1-acetylqui- 
noline thiosemicarbazones and thiosemicarbazides (class VII), and miscellaneous 
compounds related to 2-acetylpyridine thiosemicarbazones (class VIII). Each of these 
classes of compounds will be discussed, followed by a general discussion of all 
derivatives studied to date. 
Class I compounds are the most promising of the derivatives studied to date. This 
class contains those chemicals with high in vitro therapeutic indexes, low dermal 
toxicity, and significant activity in the cutaneous herpes guinea pig model. The nine 
compounds in this class which were evaluated in the guinea pig model are listed in 
Table 9 together with their dermal toxicity scores, their in vitro therapeutic indexes and 
an indication of whether they produced a statistically significant reduction in total 
lesion score in the animal model. The compounds listed in this table are ranked in 
decreasing order of in vitro therapeutic indexes. There is a positive correlation between 
in vitro therapeutic index and activity in the cutaneous herpes guinea pig model; 
namely, in vitro therapeutic indexes 1> 17 correlate with activity in the animal model. 
Although it is tempting to ascribe this predictability to the validity of our biochemical 
screening method, in actuality we are quite unable to explain this phenomenon. As can 
be seen from a further examination of this table, there is neither a positive nor a 
negative correlation with dermal toxicity. The possibility that in vitro therapeutic 
index correlates with potency of the compounds in inhibiting viral replication and thus 
potent compounds are the only ones capable of efficacy in the guinea pig model can be 
rejected after examining Table 1. 
In contrast to the monosubstituted compounds, N4,N4-disubstituted noncyclic com- 
pounds with one exception (compound 30) elicit severe dermal toxicity when tested on 
guinea pig skin. The dimethyl derivative (compound 27), with an in vitro therapeutic 
index of 19 against HSV-1, did produce a significant reduction of lesion score in the 
TABLE 9 
A comparison of class I compounds evaluated in the cutaneous herpes guinea pig model 
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Compound No. In vitro Dermal Reduction of 
therapeutic toxicity b total lesion 
index a score in 
guinea pigs c 
1 144 + Yes 
2 116 0 Yes 
21 55 :5: Yes 
17 27 + Yes 
5 17 :5: Yes 
26 12 + No 
25 6 0 No 
18 <4 0 No 
24 < 4 ++ No 
a. b. c See footnotes to Tables 1-8. 
cutaneous herpes guinea pig model. Because of the severe dermal toxicity, however, 
this compound would not be suitable for chemotherapy. In a separate experiment 
(data not shown), guinea pigs were dosed with decreasing amounts  of this compound 
in an at tempt to find a concentration of d:ug which would produce a significant 
antiviral effect without the concomitant dermal toxicity. Unfortunately, the highest 
concentration of drug not producing significant dermal toxicity was without signifi- 
cant antiviral activity. 
Three of the class I I I  compounds (46, 50, and 51) produced significant reductions of  
lesion scores in the cutaneous herpes guinea pig model. Again, however, these com- 
pounds produced a concomitant  severe dermal toxicity and would not be suitable for 
chemotherapy. 
Two 2-(2-methylpropionyl)pyridine thiosemicarbazone derivatives (class IV) were 
evaluated in the cutaneous herpes guinea pig model. Although both compounds (66 
and 68) produced no dermal toxicity, neither compound showed any significant 
activity in the infected-animal model. 
An examination of the 2-acetyl-6-methylpyridine thiosemicarbazone derivatives 
(class V) with their 2-acetylpyridine thiosemicarbazone counterparts (compare com- 
pounds 69 with 5, 71 with 44, and 73 with 50) suggests that the addition of the 6-methyl 
substituent increases the in vitro toxicity of these compounds.  Indeed, the in vitro 
therapeutic indexes of the three compounds tested in this group are ~<0.5 indicating 
that they are negatively selective when viewed as potential antiviral drugs. 
Class VI and VII compounds,  when considered collectively, exhibited relatively low 
in vitro therapeutic indexes and when active in the cutaneous herpes guinea pig model 
also produced moderate or severe dermal toxicity (compounds 87 and 96). 
None of the compounds in class VIII  were effective in inhibiting lesion formation in 
the infected guinea pig model. Compound  106, however, is of  considerable interest. 
This compound,  2-acetylpyridine semicarbazone, is a relatively potent inhibitor of  
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bo th  H S V - I  and  HSV-2  in vi t ro  while p roduc ing  little inh ib i t ion  o f  cel lular  p ro te in  or  
D N A  synthesis.  A compar i son  o f  50% inhib i tory  concen t ra t ions  in the manne r  
descr ibed  prev ious ly  in this c o m m u n i c a t i o n  yie lded in vi t ro  the rapeu t i c  indexes 
agains t  HSV-1 and  HSV-2  o f  140, a value app rox i ma te ly  equal  to  tha t  ob t a ined  with 
2-ace ty lpyr id ine  th iosemica rbazone .  The semica rbazone  p r o d u c e d  very sl ight  dermal  
toxic i ty  in the guinea  pig but  was to ta l ly  wi thout  cura t ive  effect in the cu taneous  herpes  
guinea  pig model .  A l though  this s t ruc tu re -ac t iv i ty  re la t ionsh ip  is not  unde r s tood ,  it 
may  be that  the s emica rbazone  is not  t r anspo r t ed  across  the skin whereas  its 
t h io semica rbazone  ana log  is. 
A n o t h e r  interes t ing s t ruc tu re -ac t iv i ty  re la t ionsh ip  to be der ived  f rom a s tudy of  the 
111 c o m p o u n d s  is the obse rva t ion  tha t  a reduc t ion  o f  the azometh ine  b o n d  in the 
molecule  (i.e., convers ion  o f  a t h io semica rbazone  to a th iosemica rbaz ide )  great ly  
d iminishes  de rma l  toxic i ty  appa ren t l y  wi thout  p roduc ing  a p r o p o r t i o n a l  decrease  in 
ant iv i ra l  activity.  Seven pairs  o f  c o m p o u n d s  were avai lab le  for  s tudy where  the only 
modi f i ca t ion  to the molecule  was the reduc t ion  of  the azometh ine  bond .  These pa i r ed  
c o m p o u n d s  are l isted in Table  10 toge ther  with 50% inh ib i to ry  concen t ra t ions  for  
inh ib i t ion  o f  H S V - I  and  de rma l  toxic i ty  scores. Cons ider ing  a score of  ' + '  to be 
equivalent  to 1/2+, the summed  dermal  toxic i ty  score for  the seven non reduced  com-  
p o u n d s  is 18+; this is in m a r k e d  con t ras t  to the s u m m e d  de rma l  toxic i ty  score o f  11/2+ 
for the seven reduced  c o m p o u n d s .  Viral  rep l ica t ion  d a t a  for  three of  the pairs  (46-100, 
TABLE 10 
A comparison of paired thiosemicarbazones and thiosemicarbazides of 2-acetylpyridine and related com- 
pounds 
Compound No. Dermal toxicity a 50% Inhibitory concentrations 
HSV-1 (I.tg/ml) 
33 4-++ b NT c 
99 0 0.3 
46 + + +  0.21 
100 0 0.28 
76 4-++ NT 
77 0 0.11 
81 4-4-4- NT 
82 0 0.15 
85 4- 0.87 
86 + 2.2 
88 4-4- NT 
89 0 0.33 
96 +4-4- 0.22 
97 4- 0.17 
a Saturated solutions (0.7-1.0%) of the test compound in 1,3-butanediol were applied twice per day for 5 
days to the shaved and depilated backs of guinea pigs. 
b Scores: 0 = no dermal toxicity; + = very slight toxicity; + = slight toxicity; ++  = moderate toxicity; +++  
= severe toxicity. See text for details. 
c NT = Not tested. 
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85-86, and 86-97) does not seem to indicate that reduction of the azomethine group 
has a significant effect on the antiviral activity of the compounds. Both compounds 46 
and 100 have been tested in the cutaneous herpes guinea pig model. In this case, 
reduction of the azomethine bond appears to have eliminated in vivo antiviral activity. 
Mechanism-of-action studies performed at The University of Michigan [28] strongly 
suggest that the potent antiviral activity of these compounds against herpes simplex 
virus type 1 is due to the selective inhibition of the virus-coded [14] ribonucleoside 
diphosphate reductase. This finding is in agreement with a report by Moore and 
Sartorelli that the cellular ribonucleotide reductase is inhibited by other closely relat- 
ed heterocyclic carboxaldehyde thiosemicarbazones [21]. 
From these data, it appears that there is potential clinical application for topical 
delivery of several 2-acetylpyridine thiosemicarbazones, especially those which are 
N4-monosubstituted. Selected members of this group are potent inhibitors of herpes 
simplex virus in vitro, inhibit cellular functions to a lesser extent than viral functions, 
and are able to cross intact skin readily as evidenced by their efficacy in the cutaneous 
herpes guinea pig model. 
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